Previous Article | Next Article 
Journal of Virology, March 2001, p. 2331-2336, Vol. 75, No. 5
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2331-2336.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human Papillomavirus Type 16 Minor Capsid Protein L2 N-Terminal
Region Containing a Common Neutralization Epitope Binds to the Cell
Surface and Enters the Cytoplasm
Yukiko
Kawana,1,2
Kei
Kawana,1,2
Hiroyuki
Yoshikawa,2
Yuji
Taketani,2
Kunito
Yoshiike,1 and
Tadahito
Kanda1,*
Division of Molecular Genetics, National
Institute of Infectious Diseases, Shinjuku-ku, Tokyo
162-8640,1 and Department of Obstetrics
and Gynecology, Faculty of Medicine, University of Tokyo,
Bunkyo-ku, Tokyo 113-0033,2 Japan
Received 24 August 2000/Accepted 29 November 2000
 |
ABSTRACT |
The first step of papillomavirus infection is believed to be
binding of major capsid protein L1 to the cell surface without involvement of minor capsid protein L2, but the viral infectivity can
be neutralized either by anti-L1 or anti-L2 antibody. To understand the
role of L2 in human papillomavirus (HPV) infection, we examined a
segment of HPV type 16 (HPV16) L2, which contains a neutralization epitope common to HPV6, for its involvement in adsorption and penetration of the capsids. Preincubation of monkey COS-1 cells with a
synthetic peptide having amino acids (aa) 108 to 120 of HPV16 L2
reduced the susceptibility of COS-1 cells to infection with HPV16
pseudovirions. Confocal microscopy showed that the green fluorescence
protein (GFP) fused with the L2 peptide was found to bind to the
surface of a HeLa cell, an HPV18-positive human cancer cell line, at
4°C and to enter the cytoplasm after subsequent incubation at 37°C.
Flow cytometry showed that fused GFP did not bind to HeLa cells that
had been treated with trypsin. Besides COS-1 and HeLa cells, some human
and rodent cell lines were detected by flow cytometry to be susceptible
to binding with fused GFP, showing a tendency of epithelial cells
toward higher susceptibility. Substitutions at aa 108 to 111 inhibited
fused GFP from binding to HeLa cells and reduced the infectivity in COS-1 cells of the in vitro-constructed pseudovirions. The results suggest that L2 plays an important role in enhancing HPV infection through interaction between the N-terminal region and a cellular surface protein, facilitating penetration of the virions and
determining part of the tropism of HPVs.
 |
INTRODUCTION |
Papillomaviruses, whose
nonenveloped, icosahedral, 55-nm-diameter virions are made of 72 pentameric capsomeres composed of the structural proteins L1 and L2 at
an estimated molar ratio of 30 to 1, have been found in various animal
species, including humans (26). Human papillomaviruses
(HPVs) have to date been classified into more than 80 genotypes, which
constitute two groups: cutaneous and mucosal HPVs (26).
HPVs infecting the cutaneous epithelium such as types 1, 2, 4, and 8 mainly cause skin warts (26). HPVs infecting the mucosal
epithelium such as types 6 and 11 cause benign condyloma, but types 16, 18, and 33 cause cervical cancer (14, 26). Among the nine
major types of HPV associated with cervial cancer, HPV16 is the most
prevalent type, constituting approximately 50% of cases (14,
27).
Because it is almost impossible to efficiently grow HPVs in cell
cultures, except HPV18 in a raft culture (16), surrogate systems have been developed for production of capsids (particles without viral DNA) and for assay of viral infectivity. The capsids produced in surrogate systems resemble morphologically and
immunlogically the natural virions (7, 11, 12, 22). When
L1 alone is expressed in eukaryotic cells by recombinant baculovirus or
vaccinia virus (7, 11, 12, 22), L1 can self-assemble to
form icosahedral particles (L1 capsids). When L2, which is not required
for assembly, is coexpressed with L1, both L1 and L2 are incorporated
into the particles (L1-L2 capsids) (7, 12). Furthermore,
infectious HPV pseudovirions are produced in cultured cells (19,
24). Also, pseudovirions are constructed in vitro from
disassembled capsids and a plasmid capable of expressing a reporter
gene, and their infectivity can be assayed in COS-1 cells
(9). The capsids and pseudovirions and natural bovine
papillomavirus type 1 (BPV1) virions, isolated from cutaneous legions,
have been used for studies of adsorption of papillomaviruses and of
neutralization of their infectivity.
Viral infection in vitro is supposed to start from attachment of
virions to the cell surface (20, 25). The adsorption appears to occur from binding of L1 to cell receptors without involvement of L2, because virions of BPV1 (20) and L1-L2
and L1 capsids of BPV1, HPV11, HPV16, and HPV33 (17, 20,
25) are seemingly capable of binding to cells with similar
efficiencies and because a mouse anti-BPV1 L2 monoclonal antibody,
which inhibits the infectivity of BPV1 (focus formation in mouse C127
cells), allows binding of BPV1 virions to C127 cells (18).
Thus, L2 may not be a major factor required for adsorption, but it
appears to affect infectivity, presumably at a postadsorption step,
based on the findings that infectivity is higher with the L1-L2
pseudovirons than with the L1 pseudovirons (9, 24).
Although it is not yet clear how L2 affects infectivity, studies of
neutralization with anti-L2 antibodies (1, 3, 4, 6, 10, 13,
21) suggest that the initial interaction between L2 and the cell
surface is important.
We have shown that anti-L2 antibodies that inhibit HPV16 pseudovirion
infection recognize a linear epitope localized within the L2 N-terminal
region from amino acids (aa) 108 to 120 [L2(108-120)] (8,
10). The amino acid sequence of this region is highly conserved
in other mucosal HPVs (Sequence Database of Los Alamos National
Laboratory [10]), and the neutralization epitope is common to HPV16 and HPV6 (10). It is likely, therefore,
that this L2 region has an important function in HPV infection.
To understand the role and behavior of L2 in HPV infection, we examined
the HPV16 L2 region from aa 108 to 126 [L2(108-126)] for its
interaction with cells with regard to infectivity in this study. A
competition assay showed that the L2(108-120) peptide interfered with
the infectivity of HPV16 pseudovirions in COS-1 cells, suggesting the
presence of a receptor for L2 on the cell surface. Experiments using
green fluorescence protein (GFP) (2) fused with
L2(108-126) indicated the attachment of the peptide on the cell
surface and its entry to the cytoplasm. The pseudovirions containing
mutated L2 that lacked the ability to bind showed reduced infectivity,
suggesting that the binding of L2 to the surface protein is required
for efficient HPV infection.
 |
MATERIALS AND METHODS |
Cells.
Human cell lines derived from cervical cancer (HeLa,
SiHa, and CaSki) and from liver cancer (HepG2 and Alexander), a human cell line transformed with the adenovirus E1 gene (293), a
monkey epithelial cell line (COS-1), and rodent cell lines (C127, NIH 3T3, and 3Y1) were cultured in Dulbecco's modified Eagle's medium (GIBCO BRL, New York, N.Y.) with 10% fetal calf serum (FCS) at 37°C
and with 5% CO2. The mouse myeloma cell line PAI was
cultured in RPMI 1640 (GIBCO BRL) with 10% FCS. For suspension
culture, HeLa cells were grown in S-MEM minimum essential medium (GIBCO BRL) in spinner flasks. A insect cell line (Sf9) was grown at 27°C in
optimized serum-free medium (Sf-900 II SFM; GIBCO BRL) supplemented
with 3% FCS.
Construction of pseudovirions and infectivity assay.
Infectious pseudovirions were constructed in vitro through reassembly
of disassembled L1 or L1-L2 capsids in the presence of a plasmid
capable of expressing
-galactosidase as described previously
(9). The pseudovirions were allowed to infect COS-1 cells,
and infectivity was measured by counting blue cells as described
previously (9). For large-scale preparation of capsids, Sf9 cells infected with the recombinant baculovirus were cultured by
using a cell culture controller, CELLMASTER model 1700 (Wakenyaku, Kyoto, Japan). DNase I-resistant plasmid DNA in pseudovirions was
measured by quantitative PCR with an ABI PRISM7700 sequence detector
(PE Applied Biosystems, Foster City, Calif.). Since infectivity of
pseudovirions declined during storage at 4°C, pseudovirions were
freshly prepared before use in this study.
Pseudovirions containing L2 with amino acid substitutions were newly
constructed. The DNA fragment encoding the HPV16 L2 region of aa 99 to
124, which contained an amino acid substitution of GGDD for LVEE, was
generated by PCR using the primers
5'-GGGCCCTTCTGATCCTTCTATAGTTTCTGGTGGTGATGATACTAGT-3' and
5'-GGGCCCAGGTACAGATGTTGGTGCACC-3' and a plasmid for
GFP-L2(108-126), which contained an amino acid substitution of GGDD
for LVEE as a template. The resultant DNA was inserted into the
complete L2 fragment of the pUC/HPV16L2 plasmid at the ApaI
site. Then, an EcoRI fragment of 1.5 kb was isolated and
inserted into pEGFP-C1 (Clontech Laboratories, Inc., Palo Alto, Calif.)
at its EcoRI site. After digestion with ApaLI,
plasmid DNA was diluted and self-ligated to remove the shortest
ApaLI fragment. The total L2 region with mutations was
inserted between the SmaI and XhoI sites of the
previously constructed pBacDual vector for HPV16 L1 and L2
(8). A recombinant baculovirus for L1-L2 capsids containing L2 with the substitution were generated, and pseudovirions were constructed in vitro through reassembly of disassembled L1-L2 capsids in the presence of a plasmid capable of expressing
-galactosidase as described previously (9).
GFPs fused with HPV16 L2 segment aa 108 to 126.
The GFP gene
(2) was amplified by PCR from phGFP-S65T(Clontech
Laboratories, Inc.) using the sense primer
5'-GGATCCATGGTGAGCAAGGGCGA-3' and the antisense primer
5'-AAGCTTTTACTTGTACAGCTCGTCCATGCC-3'. Three sense primers
containing HPV16 nucleotides (Sequence Database of Los Alamos National
Laboratory) 358 to 378, 343 to 375, and 322 to 359 in their 5' regions
(5'-CCAACATCTGTACCTTCCATTATGGTGAGCAAGGGCGA-3', 5'-ATTGATGCTGGTGCACCAACATCTGTACCTTCC-3', and
5'-GGATCCTTAGTGGAAGAAACTAGTTTTATTGATGCTGGTGCACC-3') and the
antisense primer were used for three successive PCRs to generate a DNA
fragment encoding GFP-L2(108-126). DNA fragments encoding mutated
GFP-L2(108-126) were constructed similarly using a DNA fragment of
GFP-LP(108-126) for the template and the antisense primer used to
generate GFP-LP(108-126). The sense primers
5'-ATTGATGCTCTGCTGCCAACATCTGTACCTTCC-3' and 5'-GGATCCTTAGTGGAAGAAACTAGTTTTATTGATGCTCTGCTGC C-3'
were used to substitute LL for GA; the primers
5'-ATTGATGCTCCACCACCAACATCTGTACCTTCC-3' and
5'-GGATCCTTAGTGGAAGAAACTAGTTTTATTGATGCTCCACCACC-3' were used for substitutions of PP for GA; and the primer
5'-GGATTCGGTGGTGATGATACTAGTTTTATTGATGCTGGTGCACCAACATC-3' was
used for substitutions of GGDD for LVEE. The amplified DNA was
subcloned into pGEMT (Promega Corp., Madison, Wis.), and the structure
of the plasmid was verified by DNA sequencing. The DNA fragments
encoding GFP or GFP-L2(108-126) were inserted into the pFastBacHT
donor plasmid (GIBCO BRL) between the BamHI and
HindIII sites, and the resultant plasmid was introduced
into DH10Bac competent bacterial cells to obtain Bacmid DNA. The
recombinant baculovirus propagated in Sf9 cells that were transfected
with Bacmid DNA generated in DH10Bac. Histidine-tagged GFPs expressed
in Sf9 cells were purified from cell lysate using an Ni column (GIBCO
BRL) according to the manufacturer's standard protocol. The purity and
concentration of GFPs were examined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. All GFPs used in this study
gave strong fluorescence under UV radiation with similar efficiencies.
Confocal microscopy.
To HeLa and the other cells (2 × 105) grown on a glass slide (Lab-Tek chamber slide; Nalge
Nunc International Corp., Naperville, Ill.) was added GFP or
GFP-L2(108-126) at 4 µg/ml in plain Dulbecco's modified Eagle's
medium after removal of the culture medium. The cells were allowed to
react with the GFPs at 4°C for 1 h and washed with plain medium twice
for removal of unbound GFPs. In some cases the cells were incubated
with GFP or GFP-L2(108-126) at 4°C for 1 h, washed twice, and
further incubated in culture medium at 37°C for 2 h. Then, the cells
that had been allowed to react with GFPs were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 5 min at
37°C, permeated in PBS containing 0.1% Triton X-100 for 10 min, and
washed three times with TBS (50 mM Tris-HCl [pH 7.5], 150 mM NaCl).
To stain nuclei, the slide cultures were soaked with 20 mg of propidium
iodide per ml for 10 min and washed with TBS three times. Fluorescence
was examined with a model LSM510 laser scanning system (Carl Zeiss Co.
Ltd., Oberkochen, Germany).
Assay for binding of GFPs to the cell surface by
fluorescence-activated cell sorter analysis.
Cells grown in a
culture plate were dispersed with PBS containing EDTA (2.5 mM) and
washed with S-MEM. HeLa cells in suspension culture were collected by
centrifugation. Cells (4 × 105) were resuspended in 2 ml of plain S-MEM containing GFP, GFP-L2(108-126), or other fused GFPs
(4 µg/ml); incubated at 4°C for 1 h; and washed twice. The
fluorescence of cells was analyzed with a FACSCalibur (Becton Dickinson
Immunocytometry Systems, Inc., Franklin Lakes, N.J.).
 |
RESULTS |
Lowered susceptibility of COS-1 cells preincubated with HPV16
L2(108-120) to infection with pseudovirions.
In an attempt to
visualize the interaction of the L2 peptide that contains a common
neutralization epitope with cells, we prepared GFP-L2(108-126) (Fig.
1). Preliminary experiments by confocal
microscopy showed that the GFP fusion peptide bound to the surfaces of
COS-1 cells, a monkey epithelial cell line positive for simian virus 40 T antigen that has been used for an HPV pseudovirion infection assay
(9), and HeLa cells, a cell line derived from HPV18-positive human cervical cancer. To correlate peptide binding with
pseudovirion infection, we tested whether the peptide affects infection
by competing with L2 in virions for binding to the surfaces of COS-1
cells.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of synthetic peptides and GFP-L2
fusion proteins used in this study. HPV16 L2 amino acids are deduced
from the HPV16R nucleotide sequence (Sequence Database of Los
Alamos National Laboratory). The entire L2 peptide consists of
473 aa. GFP-L2 fusion proteins were expressed in insect Sf9 cells
by recombinant baculoviruses and purified by affinity column
chromatography. GFP is composed of 238 aa (2).
His × 6, six histidines.
|
|
COS-1 cells (4 × 10
5) were dispersed with EDTA-PBS,
washed with PBS once, and incubated at 4°C with occasional agitation
in
80 µl of PBS containing none or one of the following competitors:
P-108/120 [a synthetic peptide with the sequence of HPV16
L2(108-120)],
P-1/12 (a peptide with the sequence of HPV16 L2 from aa
1 to 12),
GFP, or GFP-L2(108-126). One hour later, the cells were
infected
with L1-L2 or L1 pseudovirions, incubated another hour, and
then
seeded in the growth medium. Inoculum used for each infection
contained 100 ng of L1. Cells expressing

-galactosidase were
counted
after an incubation of 48
h.
Peptide P-108/120 and the fusion protein GFP-L2(108-126) were found to
interfere with the infectivity of L1-L2 pseudovirions
but not
that of L1 pseudovirions (Fig.
2). By preincubation of
COS-1 cells with
P-108/120 or GFP-L2, the number of blue cells
produced by infection
with L1-L2 pseudovirions was dropped to
less than half of
that obtained by preincubation without the peptide.
Since incubation
with P-1/12 or plain GFP did not reduce the number
of blue cells, the
reduction required the amino acid sequence
of the L2 peptide. The
numbers of blue cells produced by infection
with L1
pseudovirions, which were less infectious than L1-L2
pseudovirions,
were not influenced by preincubation with
the L2 peptide. The
data indicate that the peptide containing the
common neutralization
epitope competes with the L2 region displayed on
the surfaces
of HPV virions for binding to a cellular surface protein,
suggesting
that the binding to the cellular target is important for L2
to
enhance infectivity. For the cells whose surface targets for L2
were
saturated with P-108/120 or GFP-L2(108-126), L1-L2
pseudovirions
may have lost the advantage of having L2 and
behaved like L1 pseudovirions
in the infectivity assay.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Susceptibility of COS-1 cells preincubated with the L2
peptide to infection with pseudovirions. COS-1 cells
(4 × 105) were incubated in PBS (80 µl) containing
the L2 peptide P-108/120, P-1/12, GFP-L2(108-126), or GFP for
1 h prior to infection with L1-L2 or L1
pseudovirions. The number of blue cells expressing
-galactosidase was counted 48 h after infection with
pseudovirions. Results of three independent
experiments are presented with standard deviations (T bars).
|
|
Binding of the L2 peptide to HeLa cells.
Confocal microscopy
showed that GFP-L2(108-126) bound to the surface of a HeLa cell, a
cell line derived from HPV18-positive cervical cancer. HeLa cells
cultured in suspension were allowed to react with purified GFP or
GFP-L2(108-126) at 4°C for 1 h. After washing of the cells,
fluorescence of GFP bound to the cells was scanned cross-sectionally in
a confocal microscope (Fig. 3). HeLa
cells incubated with GFP-L2(108-126) showed strong fluorescence around
the surface, which was detected as a ring (Fig. 3B), whereas those
incubated with GFP did not.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
Detection of GFP-L2 fusion protein bound to HeLa cells by
fluorescence. (A) Phase-contrast microscopy of a HeLa cell cultured in
a spinner flask. HeLa cells cultured in a spinner flask were incubated
with GFP-L2(108-126) at 4°C for 1 h (B) and with
GFP-L2(108-126) at 4°C for 1 h and at 37°C for 4 h (C).
(B and C) The section near the center of a round cell cultured in
suspension is presented. HeLa cells cultured on a glass slide were
incubated with plain GFP at 4°C for 1 h (D), with
GFP-L2(108-126) at 4°C for 1 h (E), and with GFP-L2(108-126)
at 4°C for 1 h and at 37°C for 4 h (F). (E) The section near
the surfaces of flat cells showed fluorescent dots with parts of
nuclei. (F) The section near the centers of cells showed cytoplasmic
fluorescence. Fluorescence was examined with a Carl Zeiss LSM510 laser
scanning confocal system. (D, E, and F) Nuclei were stained with
propidium iodide.
|
|
After subsequent incubation of HeLa cells at 37°C for 4 h, the
fluorescence of GFP-L2(108-126) was detected by microscopy
in the
cytoplasms of HeLa cells cultured in suspension (Fig.
3C).
Migration of
GFP-L2(108-126) from the surface to the perinuclear
region was
observed more clearly with HeLa cells cultured on a
glass slide (Fig.
3E and F). When cells were scanned in the microscope,
fluorescent dots
were seen probably over the flat surfaces of
cells, and after
incubation at 37°C, fluorescent masses were seen
around the nuclei.
The results suggest that the L2 region binds
to a cellular protein
displayed on the cell surface and that the
complex moves toward the
inside of the
cell.
Quantitative analysis by fluorescence-activated cell sorting with a
standard fluorescein isothiocyanate filter indicated that
the level of
fluorescence of HeLa cells incubated with GFP-L2(108-126)
at 4°C for
1 h and washed extensively was much higher than that
of HeLa cells
incubated with plain GFP (Fig.
4).
GFP-L2(108-126)
did not bind to HeLa cells that had been treated with
0.2% trypsin
at room temperature for 5 min (Fig.
4), indicating that a
cell
surface protein must be involved in binding.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Binding of GFP-L2 fusion protein to HeLa cells. HeLa
cells, cultured in suspension, were incubated with various GFP-L2
fusion proteins at 4°C for 1 h and washed, and then the
intensity of fluorescence of more than 2 × 105 cells
was measured with a FACSCalibur (Becton Dickinson Immunocytometry
Systems, Inc.). Relative intensities of fluorescence to HeLa cells
incubated with GFP-L2(108-126) are shown with standard deviations (T
bars) from three independent experiments. The result with HeLa cells
not incubated with GFP is indicated as "mock." "Trypsinized
HeLa" indicates cells that had been treated with 0.2% trypsin at
room temperature for 5 min before incubation with GFP-L2(108-126).
|
|
GFP-L2(108-126) was found to bind not only to HeLa and COS-1 cells but
also to some human and rodent cell lines. Because the
intensity of the
fluorescence of cells that were allowed to react
with GFP-L2(108-126)
varied from cell line to cell line in preliminary
experiments by
confocal microscopy, the intensity was measured
by flow cytometry and
presented as relative to that of the fluorescence
of HeLa cells (Fig.
5). The cells that had been cultured on
plates
were dispersed with PBS containing EDTA (2.5 mM), suspended in
fresh medium containing the GFP peptide at 4°C for 1 h, and
washed
with plain medium before measurement. The human cervical cancer
cell lines SiHa and CaSki bound GFP-L2(108-126) at a high level,
similar to the level of binding to HeLa cells, but the rodent
lymphocyte PAI cell line and insect Sf9 cell line bound almost
none of
the peptide. COS-1 cells bound the fluorescent peptide
in an amount
comparable with those bound by the cervical cancer
cell lines. The
levels of peptide that bound to other cell lines,
the human epithelial
cell-like cell line 293 (transformed by adenovirus
E1), the mouse cell
lines C127 (derived from mouse mammary tumor)
and NIH 3T3
(fibroblasts), the rat 3Y1 cell line (fibroblasts),
and the human liver
cancer lines Alexander and Hep G2, fell between
the two groups with the
strongest and weakest fluorescence. As
can be seen in Fig.
5, the
cervical cancer cells bound more GFP-L2(108-126)
than the liver cancer
cells did, and the human cells appeared
to bind more L2(108-126)
peptide than the rodent cells did. Among
rodent cells, C127 cells,
which are susceptible to HPV pseudovirions
infection
(
19), bound more L2 peptide than NIH 3T3 and 3Y1 cells
did. Thus, it seems likely that the cells from epithelial tissues
have
more target proteins for L2(108-126) on their surfaces than
those from
other tissues.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
Binding of GFP-L2(108-126) to various cell lines. The
intensity of fluorescence of more than 2 × 105 cells
incubated with GFP-L2(108-126) was measured with a FACSCalibur (Becton
Dickinson Immunocytometry Systems, Inc.). Cells were dispersed with PBS
containing EDTA. The average level of intensity specific to
GFP-L2(108-126) was calculated by subtracting the mean obtained by
incubation with plain GFP from that with GFP-L2(108-126). Intensities
of fluorescence relative to that of HeLa cells are presented with
standard deviations (T bars) from three independent experiments.
|
|
Mutational analysis of the HPV16 L2 region and infectivity of
pseudovirions containing the mutant L2 peptide unable to
bind to cell surfaces.
Analyses of HPV16 L2(108-126) showed that
LVEE at aa 108 to 111 was essential for L2 to bind to the cell surface.
Since aa 108 to 111 (LVEE) and aa 118 to 120 (GAP) are highly conserved in mucosal HPVs (10), mutants with substitutions for these
amino acids were produced as fusion proteins with GFP (Fig. 1) and
examined for their capacity to bind to the surfaces of HeLa cells by
flow cytometry (Fig. 4). While the two mutants having LL and PP
substituting for GA (aa 118 and 119) bound to the cells at a level
similar to that shown with GFP-L2(108-126), the mutant with GGDD
substituting for LVEE completely lost the ability to bind. To link the
binding assay of the peptide and the infectivity of virions, the
pseudovirions having the amino acid substitution were
constructed and examined for their infectivity in COS-1 cells.
Mutant L2 with substitution of GGDD for LVEE was packaged into
pseudovirions constructed in vitro. Capsids generated in
Sf9
cells infected with a recombinant baculovirus expressing L1 and
the
mutated L2 were extracted and purified as described previously
(
8,
9). Then mutant pseudovirions were
constructed from
the disassembled mutant capsids and reporter plasmid
DNA in vitro
and purified by CsCl centrifugation as described
previously (
9).
The fractions with a density of 1.31 g/ml,
which contained icosahedral
particles as seen by electron microscopy
(data not presented)
and plasmid DNA resistant to DNase I (data not
presented), were
sedimented in a sucrose gradient (10 to 60%) by
centrifugation
and fractionated. The presence of L1 and L2 in each
fraction was
examined by enzyme-linked immunosorbent assay using
anti-L1 and
anti-L2 antibodies (
8,
9) (Fig.
6). Clearly, L1 and L2 were
copurified in
fractions 10 to 12. The amounts of L2 in relation
to L1 in these
fractions were comparable to those of wild-type
pseudovirions (
8,
9). The data indicate that
mutated L2
was incorporated into the capsids and that the substitution
of
GGDD for LVEE did not affect the production of
pseudovirions.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Sucrose gradient sedimentation of HPV16
pseudovirions. Pseudovirions containing wild-type or mutant
L2 with the amino acid substitution of GGDD for LVEE, purified by CsCl
equilibrium density gradient centrifugation, were sedimented in a
sucrose gradient (10 to 60% [wt/vol] in PBS) by centrifugation and
fractionated (0.2 ml/fraction) from the bottom. L1 and L2 in each
fraction were denatured in carbonate buffer (pH 9.6) and measured by
enzyme-linked immunosorbent assay (ELISA) using anti-L1 and anti-L2
antibodies. Pools of fractions indicated by bars contained
approximately 4.5 × 103 copies of DNase I-resistant
indicator plasmid per ng of L1 protein. OD450nm, optical density at 450 nm.
|
|
The mutant pseudovirions [L1-L2(GGDD)] were found to be
less infectious than the wild type (L1-L2) (Table
1). For the infectivity
assay, COS-1
cells were infected, as previously described (
9),
with
freshly constructed and purified pseudovirions. It should
be noted that COS-1 cells, whose parental cell line, CV-1, can
bind
with L1 capsids (
5), were positive for binding with
GFP-L2(108-126)
(Fig.
5). Input virions were adjusted to the L1
content estimated
by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis followed
by silver staining. One nanogram of virions,
wild-type or mutant,
contained approximately 4.5 × 10
3 copies of the DNase I-resistant reporter plasmid.
Indirect immunofluorescence
staining using anti-HPV16 L1 antibody
(PharMingen, San Diego,
Calif.) showed that wild-type and mutant
pseudovirions used in
this assay bound equally to the cell
surface (data not presented).
The number of blue cells produced in
COS-1 culture infected with
the mutant pseudovirions
dropped to a level similar to that obtained
by infection with L1
pseudovirions (Table
1). Thus, the mutant
pseudovirions were less infectious than the wild-type
pseudovirions
due to the loss of the L2 effect, which
strengthens the infectivity
of the pseudovirions (
9,
24). It was concluded from these
results, along with the data in
Fig.
2, that the binding of the
L2 region that contains the common
neutralization epitope with
a surface cellular protein is necessary for
efficient HPV infection.
 |
DISCUSSION |
In this study a competition assay showed that the peptide with the
N-terminal sequence of HPV16 L2(108-120) interfered with the
infectivity of pseudovirions in COS cells, and confocal
microscopy showed that the L2(108-126) peptide tagged with GFP
attached to the HeLa cell surface at a low temperature and entered the
cytoplasm when the temperature was raised to 37°C. The competition
assay suggests the presence of a cell surface receptor for the region from aa 108 to 120 of L2, to which the GFP peptide can bind. The binding and visualized behavior of the L2 peptide (Fig. 3) are considered to reflect the behavior of L2 in the virion, because the
amino acid substitutions that prevented the peptide from binding were
found to lower the infectivity of the pseudovirion having the same mutations. Thus, the results obtained in this study suggest that L2(108-126), displayed on the surfaces of capsids
(8), is involved in an early step of HPV infection by
binding with the cellular receptor at the time of the attachment of
virions to cells.
However, binding of L2 to the cell receptor may be unnecessary for
adsorption because the capsids without L2 are believed to attach to
cells as efficiently as the capsids with L2 (20, 25). It
is possible that L2 binding may be a passive reaction at adsorption,
which is mediated mainly by L1. On the other hand, it is clear that L2
has a certain role in enhancing infectivity in pseudovirion
assays (Fig. 2) (18, 24). Perhaps L2 is active at a
postadsorption step: at the entry of virions into cells or otherwise at
a later step before expression of the viral genes (18).
The cell surface receptor for L2 appears to be different from those for
L1, as shown by the competition experiments in which the L2 peptide did
not interfere with the infectivity of L1 pseudovirions (Fig. 2). The L1 pseudovirions are less than half as
infectious as the L1-L2 pseudovirions (24)
(Fig. 2) and so are the pseudovirions with the substitution
mutation (Table 1). Furthermore, saturation of the surface L2 receptors
with the L2 peptide lowered the measured level of infectivity of the
L1-L2 pseudovirions to that of L1 pseudovirions
(Fig. 2). Thus, binding to L1 and L2 receptors seems to enhance
infectivity, compared with binding to L1 receptors alone. Possibly,
binding to both receptors may help in efficient internalization of the virions.
Cellular surface protein binding with L2 may determine part of the cell
tropism of mucosal HPVs. The putative receptor for L1 has been reported
to be a protein widely expressed and evolutionarily conserved among
cells derived from a variety of tissues (17, 20, 25). For
example,
6 integrin, a probable candidate for the
receptor for HPV6b (5, 15) but not the obligatory receptor for BPV4 (23), is a molecule expressed widely on the
surfaces of cells derived from various tissues. Thus, binding of L1
alone to the putative receptor does not account for the tropism of
mucosal HPVs. Since cellular protein binding with HPV16 L2 seems to be expressed more abundantly in epithelial cells, especially cells derived
from cervical cancers, than those of other origins (Fig. 5), and since
the amino acid sequence of the HPV16 L2 region is conserved in mucosal
HPVs, it is possible that conditions in cells expressing the target
protein for L2 are favorable for mucosal HPVs to infect.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant-in-aid from the Ministry of
Health and Welfare for the Second-Term Comprehensive 10-Year Strategy
for Cancer Control and by a cancer research grant from the Ministry of
Education, Science, Culture, and Sports of Japan.
We thank K. Ishii for technical assistance in confocal microscopy.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Molecular Genetics, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: (81)-3-5285-1111,
ext. 2524. Fax: (81)-3-5285-1166. E-mail:
kanda{at}nih.go.jp.
 |
REFERENCES |
| 1.
|
Campo, M. S.,
B. W. O'Neil,
G. J. Grindlay,
F. Curtis,
G. Knowles, and L. M. Chandrachud.
1997.
A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease.
Virology
234:261-266[CrossRef][Medline].
|
| 2.
|
Chalfie, M.,
T. Tu,
G. Euskirchen,
W. W. Ward, and D. C. Prasher.
1994.
Green fluorescent protein as a marker for gene expression.
Science
263:802-805[Abstract/Free Full Text].
|
| 3.
|
Chandrachud, L. M.,
G. J. Grindlay,
G. M. McGarvie,
B. W. O'Neil,
E. R. Wagner,
W. F. H. Jarrett, and M. S. Campo.
1995.
Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4.
Virology
211:204-208[CrossRef][Medline].
|
| 4.
|
Christensen, N. D.,
J. W. Kreider,
N. C. Kan, and S. L. Diangelo.
1991.
The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes.
Virology
181:572-579[CrossRef][Medline].
|
| 5.
|
Evander, M.,
I. H. Frazer,
E. Payne,
Y. M. Qi,
K. Hengst, and N. A. J. McMillan.
1997.
Identification of the 6 integrin as a candidate receptor for papillomaviruses.
J. Virol.
71:2449-2456[Abstract].
|
| 6.
|
Gaukroger, J. M.,
L. M. Chandrachud,
B. W. O'Neil,
G. J. Grindlay,
G. Knowles, and M. S. Campo.
1996.
Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies.
J. Gen. Virol.
77:1577-1583[Abstract/Free Full Text].
|
| 7.
|
Hagensee, M. E.,
N. Yaegashi, and D. A. Galloway.
1993.
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins.
J. Virol.
67:315-322[Abstract/Free Full Text].
|
| 8.
|
Kawana, K.,
K. Matsumoto,
H. Yoshikawa,
Y. Taketani,
T. Kawana,
K. Yoshiike, and T. Kanda.
1998.
A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
Virology
245:353-359[CrossRef][Medline].
|
| 9.
|
Kawana, K.,
H. Yoshikawa,
Y. Taketani,
K. Yoshiike, and T. Kanda.
1998.
In vitro construction of pseudovirions of human papillomavirus type 16:incorporation of plasmid DNA into reassembled L1/L2 capsids.
J. Virol.
72:10298-10300[Abstract/Free Full Text].
|
| 10.
|
Kawana, K.,
H. Yoshikawa,
Y. Taketani,
K. Yoshiike, and T. Kanda.
1999.
Common neutralization epitope in minor capsid protein L2 of human papillomaviruses 16 and 6.
J. Virol.
73:6188-6190[Abstract/Free Full Text].
|
| 11.
|
Kirnbauer, R.,
F. Booy,
N. Cheng,
D. R. Lowy, and J. T. Schiller.
1992.
Papillomavirus L1 major capsid protein salf-assembles into virus-like particles that are highly immunogenic.
Proc. Natl. Acad. Sci. USA
89:12180-12184[Abstract/Free Full Text].
|
| 12.
|
Kirnbauer, R.,
J. Taub,
H. Greenstone,
R. Roden,
M. Durst,
L. Gissmann,
D. R. Lowy, and J. T. Schiller.
1993.
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.
J. Virol.
67:6929-6936[Abstract/Free Full Text].
|
| 13.
|
Lin, Y.-L.,
L. A. Borenstein,
R. Selvakumar,
R. Ahmed, and F. O. Wettstein.
1992.
Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.
Virology
187:612-619[CrossRef][Medline].
|
| 14.
|
Lorincz, A. T.,
R. Reid,
A. B. Jensen,
M. D. Greenberg,
A. A. W. Lancaster, and R. J. Kurman.
1991.
Human papillomavirus infection of the cervix; relative risk associations of 15 common anogenital types.
Obstet. Gynecol.
79:328-337.
|
| 15.
|
McMillan, N. A. J.,
E. Payne,
I. H. Frazer, and M. Evander.
1999.
Expression of the 6 integrin confers papillomavirus binding upon receptor-negative B-cells.
Virology
261:271-279[CrossRef][Medline].
|
| 16.
|
Meyers, C.,
T. J. Mayer, and M. A. Ozbuin.
1997.
Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA.
J. Virol.
71:7381-7386[Abstract].
|
| 17.
|
Muller, M.,
L. Gissmann,
R. J. Cristiano,
X.-Y. Sun,
I. H. Frazer,
A. B. Jenson,
A. Alonso,
H. Zentgraf, and J. Zhou.
1995.
Papillomavirus capsid binding and uptake by cells from different tissues and species.
J. Virol.
69:948-954[Abstract].
|
| 18.
|
Roden, R. B. S.,
E. M. Weissinger,
D. W. Henderson,
F. Booy,
R. Kirnbauer,
J. F. Mushinski,
D. R. Lowy, and J. T. Schiller.
1994.
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.
J. Virol.
68:7570-7574[Abstract/Free Full Text].
|
| 19.
|
Roden, R. B. S.,
H. L. Greenstone,
R. Kirnbauer,
F. P. Booy,
J. Jessie,
D. R. Lowy, and J. T. Schiller.
1996.
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
J. Virol.
70:5875-5889[Abstract].
|
| 20.
|
Roden, R. B. S.,
R. Kirnbauer,
A. B. Jenson,
D. R. Lowy, and J. T. Schiller.
1994.
Interaction of papillomaviruses with the cell surface.
J. Virol.
68:7260-7266[Abstract/Free Full Text].
|
| 21.
|
Roden, R. B. S.,
W. H. Yutzy, IV,
R. Fallon,
S. Inglis,
D. R. Lowy, and J. T. Schiller.
2000.
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Virology
270:254-257[CrossRef][Medline].
|
| 22.
|
Rose, R. C.,
W. Bonnez,
R. C. Reichman, and R. L. Garcea.
1993.
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.
J. Virol.
67:1936-1944[Abstract/Free Full Text].
|
| 23.
|
Sibbet, G.,
C. Romero-Graillet,
G. Meneguzzi, and M. S. Campo.
2000.
6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4.
J. Gen. Virol.
81:327-334[Abstract/Free Full Text].
|
| 24.
|
Unckell, F.,
R. E. Streeck, and M. Sapp.
1997.
Generation and neutralization of pseudovirions of human papillomavirus type 33.
J. Virol.
71:2934-2939[Abstract].
|
| 25.
|
Volpers, C.,
F. Unckell,
P. Schirmacher,
R. E. Streeck, and M. Sapp.
1995.
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells.
J. Virol.
69:3258-3264[Abstract].
|
| 26.
|
zur Hausen, H.
1996.
Papillomavirus infections a major cause of human cancers.
Biochim. Biophys. Acta
1288(Suppl. 2):F55-F78[Medline].
|
| 27.
|
zur Hausen, H.
2000.
Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.
J. Natl. Cancer Inst.
92:690-698[Abstract/Free Full Text].
|
Journal of Virology, March 2001, p. 2331-2336, Vol. 75, No. 5
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2331-2336.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fahey, L. M., Raff, A. B., Da Silva, D. M., Kast, W. M.
(2009). A Major Role for the Minor Capsid Protein of Human Papillomavirus Type 16 in Immune Escape. J. Immunol.
183: 6151-6156
[Abstract]
[Full Text]
-
Alphs, H. H., Gambhira, R., Karanam, B., Roberts, J. N., Jagu, S., Schiller, J. T., Zeng, W., Jackson, D. C., Roden, R. B. S.
(2008). Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc. Natl. Acad. Sci. USA
105: 5850-5855
[Abstract]
[Full Text]
-
Gambhira, R., Jagu, S., Karanam, B., Gravitt, P. E., Culp, T. D., Christensen, N. D., Roden, R. B. S.
(2007). Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2. J. Virol.
81: 11585-11592
[Abstract]
[Full Text]
-
Nakanishi, A., Itoh, N., Li, P. P., Handa, H., Liddington, R. C., Kasamatsu, H.
(2007). Minor Capsid Proteins of Simian Virus 40 Are Dispensable for Nucleocapsid Assembly and Cell Entry but Are Required for Nuclear Entry of the Viral Genome. J. Virol.
81: 3778-3785
[Abstract]
[Full Text]
-
Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J. A.
(2006). Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol.
80: 2621-2630
[Abstract]
[Full Text]
-
Holmgren, S. C., Patterson, N. A., Ozbun, M. A., Lambert, P. F.
(2005). The Minor Capsid Protein L2 Contributes to Two Steps in the Human Papillomavirus Type 31 Life Cycle. J. Virol.
79: 3938-3948
[Abstract]
[Full Text]
-
Fay, A., Yutzy, W. H. IV, Roden, R. B. S., Moroianu, J.
(2004). The Positively Charged Termini of L2 Minor Capsid Protein Required for Bovine Papillomavirus Infection Function Separately in Nuclear Import and DNA Binding. J. Virol.
78: 13447-13454
[Abstract]
[Full Text]
-
Selinka, H.-C., Giroglou, T., Nowak, T., Christensen, N. D., Sapp, M.
(2003). Further Evidence that Papillomavirus Capsids Exist in Two Distinct Conformations. J. Virol.
77: 12961-12967
[Abstract]
[Full Text]
-
Varsani, A., Williamson, A.-L., de Villiers, D., Becker, I., Christensen, N. D., Rybicki, E. P.
(2003). Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16. J. Virol.
77: 8386-8393
[Abstract]
[Full Text]
-
Finnen, R. L., Erickson, K. D., Chen, X. S., Garcea, R. L.
(2003). Interactions between Papillomavirus L1 and L2 Capsid Proteins. J. Virol.
77: 4818-4826
[Abstract]
[Full Text]
-
Yang, R., Yutzy, W. H. IV, Viscidi, R. P., Roden, R. B. S.
(2003). Interaction of L2 with beta -Actin Directs Intracellular Transport of Papillomavirus and Infection. J. Biol. Chem.
278: 12546-12553
[Abstract]
[Full Text]
-
Yang, R., Day, P. M., Yutzy, W. H. IV, Lin, K.-Y., Hung, C.-F., Roden, R. B. S.
(2003). Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection. J. Virol.
77: 3531-3541
[Abstract]
[Full Text]
-
Embers, M. E., Budgeon, L. R., Pickel, M., Christensen, N. D.
(2002). Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein. J. Virol.
76: 9798-9805
[Abstract]
[Full Text]
-
Florin, L., Sapp, C., Streeck, R. E., Sapp, M.
(2002). Assembly and Translocation of Papillomavirus Capsid Proteins. J. Virol.
76: 10009-10014
[Abstract]
[Full Text]
-
Wellnitz, S., Klumpp, B., Barth, H., Ito, S., Depla, E., Dubuisson, J., Blum, H. E., Baumert, T. F.
(2002). Binding of Hepatitis C Virus-Like Particles Derived from Infectious Clone H77C to Defined Human Cell Lines. J. Virol.
76: 1181-1193
[Abstract]
[Full Text]
-
Roden, R. B. S., Day, P. M., Bronzo, B. K., Yutzy, W. H. IV, Yang, Y., Lowy, D. R., Schiller, J. T.
(2001). Positively Charged Termini of the L2 Minor Capsid Protein Are Necessary for Papillomavirus Infection. J. Virol.
75: 10493-10497
[Abstract]
[Full Text]